2025 – Page 3 – Clinical Trial Results

Dr. Jeffrey I Weitz and Dr. C. Michael Gibson Discuss: ROXI~ Two Mechanistically Distinct Factor XI Antibodies, REGN9933 and REGN7508, for the Prevention of Venous Thromboembolism After Knee Arthroplasty: the ROXI-VTE-I and ROXI-VTE-II trials

November 8, 2025

Disclosures: TBD

Dr. Paul Burton and Dr. C. Michael Gibson Discuss: Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial

November 8, 2025

Disclosures: TBD

Dr. Robin Nijveldt and Dr. C. Michael Gibson Discuss: iMODERN:iFR- vs. Cardiac MRI-Guided Revascularization of Non-Culprit Lesions in STEMI

October 28, 2025

Disclosures: TBD

Dr. Shamir R. Mehta and Dr. C. Michael Gibson Discuss: STRIVE:Low-Dose r-tPA vs. Placebo in STEMI With Large Thrombus Burden

October 28, 2025

Disclosures: TBD

Dr. Ruben de Winter and Dr. C. Michael Gibson Discuss: PROCTOR:Native Vessel vs. SVG PCI in Patients With Prior CABG

October 28, 2025

Disclosures: TBD

Dr. Matthias Bossard and Dr. C. Michael Gibson Discuss: VICTORY:Intravascular Lithotripsy vs. Super-High-Pressure PTCA in Calcified and Refractory Coronary Lesions

October 26, 2025

Disclosures: TBD

Dr. Donald Cutlip and Dr. C. Michael Gibson Discuss: SELUTION4ISR: Sirolimus-Eluting DCB vs. DES or Balloon Angioplasty for In-Stent Restenosis

October 26, 2025

Disclosures: TBD

Dr. Christian M. Spaulding and Dr. C. Michael Gibson Discuss: SELUTION DeNovo: Sirolimus-Eluting DCB vs. DES in De Novo Coronary Lesions

October 26, 2025

Disclosures: TBD

Dr. Hofmann and Dr. Gibson discuss HELP-MI SWEDEHEART trial

September 5, 2025

Disclosures: TBD

Dr. Adam Castano and Dr. C. Michael Gibson discuss: ACT-EARLY, a Phase 3 Study – Clinical Trial Results

May 12, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc